Canrenoic acid

DB09015ApprovedInvestigationalWithdrawnSmall molecule

Canrenoic acid is an aldosterone antagonist used in primary hyperaldosteronism and other disorders related to aberrant aldosterone levels. Like spironolactone, it is a prodrug, which is metabolized to canrenone in the body.

Chemical structure of Canrenoic acid
Mechanism
Curator reviewed
Formula / weight
C22H30O4 · 358.478 g/mol (avg)
Also known as
Canrenoate
Code names
MF 465a · SC 14266

Resolves to

Compound
UNII87UG89VA9KCAS4138-96-9ChEMBLCHEMBL1616951ChEBI50156PubChem656615
Clinical / RWD
RxNorm618970ATCC03DA02
Structure
InChIKeyPBKZPPIHUVSDNM-WNHSNXHDSA-NSMILES[H][C@@]12CC[C@@](O)(CCC(O)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])C=CC2=CC(=O)CC[C@]12C
Targets
P08235NR3C2

What you can answer from here — as of September 23, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
910Drug interactionsStructured to mechanism, not free text
Sign in
5Clinical trialsPhase, status and sponsor resolved per trial
Sign in
6Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
6ContraindicationsEach with its own population and attribute set
Sign in
19Marketed productsAcross 2 countries and 6 labellers
Sign in
1ATC codeIncluding every combination product, plus 11 drug categories
Sign in
6+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Canrenoic acid, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In